Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05180994 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Topical Infliximab in Eyes With Penetrating Keratoplasty

StatusRecruiting
PhasePhase 1/2
Started2022-05-01
View on ClinicalTrials.gov ↗

Amendment history

2026-04-23
2 amendments v4-v5
2 re-verifications since 2024-08-21, no change to tracked fields
2023-04-28
Study Status v3
Primary completion date2023-03-01→2027-03-01
Completion date2023-03-01→2028-03-01
2022-12-19
Study Status v2
Re-verified, no change to tracked fields
2022-07-04
Not Yet Recruiting→Recruiting Study Status, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-02-01→confirmed 2022-05-01
Secondary endpointsdetails revised at 2 of 8 entries
Study sitesdetails revised at 1 of 1 site
2021-12-19
Original filing
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.
Trial Details
NCT Number NCT05180994
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Fonds de recherche en ophtalmologie de l'Université de Montréal, Maisonneuve-Rosemont Hospital, Niagara Health System, Prism Eye Institute, Ottawa Hospital Research Institute
Conditions Glaucoma Following Surgery
Enrollment 50 participants
Start Date 2022-05-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-27